Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10010882HBVENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TVIS30067833HIVENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TVIS20012857HPVENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TVIS20062294HPVENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TVIS20023366HPVENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TVIS20022730HPVENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TVIS20061784HPVENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TVIS44016703HTLV-1ENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TVIS44049057HTLV-1ENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TCGA Plot Options
Drug Information
GeneMET
DrugBank IDDB08875
Drug NameCabozantinib
Target IDBE0000915
UniProt IDP08581
Regulation Typeantagonist
PubMed IDs21606412; 21926191
CitationsKurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Muller T, Ratain MJ, Salgia R: Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 1;29(19):2660-6. doi: 10.1200/JCO.2010.32.4145. Epub 2011 May 23.@@Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011 Dec;10(12):2298-308. doi: 10.1158/1535-7163.MCT-11-0264. Epub 2011 Sep 16.
GroupsApproved; Investigational
Direct ClassificationDiarylethers
SMILESCOC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2
Pathways
PharmGKB
ChEMBLCHEMBL2105717